Related Experiment Video
Updated: May 19, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
Dopamine-mediated autocrine inhibitory circuit regulating human insulin secretion in vitro
Norman Simpson1, Antonella Maffei, Matthew Freeby
1Division of Endocrinology, Department of Medicine, Columbia University Medical College, 650 West 168th Street, BB 2006, New York, New York 10032, USA.
Insights
Dopamine (DA) released from human islet cells during glucose stimulation acts as a brake on insulin secretion. Blocking this dopamine signaling pathway enhances insulin release, potentially explaining side effects of certain medications.
Area of Science:
- Endocrinology
- Neuroscience
- Cell Biology
Background:
- Glucose-stimulated insulin secretion (GSIS) is crucial for maintaining glucose homeostasis.
- Autocrine regulatory mechanisms within pancreatic beta cells fine-tune insulin release.
- The role of neurotransmitters like dopamine in islet function is not fully elucidated.
Purpose of the Study:
- To investigate the role of dopamine in regulating glucose-stimulated insulin secretion in human islets.
- To identify the specific molecular players involved in dopamine signaling within beta cells.
- To explore the potential link between islet dopamine signaling and metabolic side effects of medications.
Main Methods:
- Purified human islets were used for in vitro experiments.
- Chronoamperometry was employed to measure dopamine release.
- In vitro glucose-stimulated insulin secretion assays were performed.
- Pharmacological antagonism of dopamine receptors (D2R) was utilized.
Main Results:
- Dopamine (DA) is released from human beta cells upon glucose stimulation.
- DA is stored in secretory granules via vesicular monoamine transporter type 2 (VMAT2).
- DA acts as a negative autocrine regulator of insulin secretion by binding to D2 receptors on beta cells.
- Antagonism of D2 receptors significantly increased glucose-stimulated insulin secretion.
Conclusions:
- A novel negative feedback loop involving dopamine in human islet autocrine regulation of insulin secretion has been identified.
- This dopamine-D2 receptor pathway provides a brake on insulin release, modulated by glucose levels.
- These findings offer insights into the metabolic consequences, such as increased adiposity, associated with atypical antipsychotic use, which can affect dopamine signaling.
Abstract:
We describe a negative feedback autocrine regulatory circuit for glucose-stimulated insulin secretion in purified human islets in vitro. Using chronoamperometry and in vitro glucose-stimulated insulin secretion measurements, evidence is provided that dopamine (DA), which is loaded into insulin-containing secretory granules by vesicular monoamine transporter type 2 in human β-cells, is released in response to glucose stimulation. DA then acts as a negative regulator of insulin secretion via its action on D2R, which are also expressed on β-cells. We found that antagonism of receptors participating in islet DA signaling generally drive increased glucose-stimulated insulin secretion. These in vitro observations may represent correlates of the in vivo metabolic changes associated with the use of atypical antipsychotics, such as increased adiposity.
Related Concept Videos
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...
Insulin Secretory Vesicles
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Insulin: The Receptor and Signaling Pathways
Regulation of Hormone Secretion
Humoral stimuli,...
Feedback Loops

